Your browser doesn't support javascript.
Acute Hypertriglyceridaemia Caused by Tocilizumab in a Patient with Severe COVID-19.
Nakamura, Hideta; Miyagi, Kazuya; Otsuki, Mariko; Higure, Yuuri; Nishiyama, Naoya; Kinjo, Takeshi; Nakamatsu, Masashi; Haranaga, Shusaku; Tateyama, Masao; Fujita, Jiro.
  • Nakamura H; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Miyagi K; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Otsuki M; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Higure Y; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Nishiyama N; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Kinjo T; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Nakamatsu M; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Haranaga S; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Tateyama M; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
  • Fujita J; Department of Infectious Disease, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Japan.
Intern Med ; 59(22): 2945-2949, 2020 Nov 15.
Article in English | MEDLINE | ID: covidwho-789033
ABSTRACT
Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Hypertriglyceridemia / Coronavirus Infections / Antibodies, Monoclonal, Humanized / Betacoronavirus Type of study: Case report / Observational study / Prognostic study Limits: Humans / Male / Middle aged Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2020 Document Type: Article Affiliation country: Internalmedicine.5244-20

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Hypertriglyceridemia / Coronavirus Infections / Antibodies, Monoclonal, Humanized / Betacoronavirus Type of study: Case report / Observational study / Prognostic study Limits: Humans / Male / Middle aged Language: English Journal: Intern Med Journal subject: Internal Medicine Year: 2020 Document Type: Article Affiliation country: Internalmedicine.5244-20